These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 30312399)

  • 21. Targeting triglycerides to lower residual cardiovascular risk.
    Bubb KJ; Nelson AJ; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2022 Mar; 20(3):185-191. PubMed ID: 35323080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetics of hypertriglyceridemia and atherosclerosis.
    Gill PK; Dron JS; Hegele RA
    Curr Opin Cardiol; 2021 May; 36(3):264-271. PubMed ID: 33818545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
    Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.
    Zhang BH; Yin F; Qiao YN; Guo SD
    Front Mol Biosci; 2022; 9():909151. PubMed ID: 35693558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association.
    Kirkpatrick CF; Sikand G; Petersen KS; Anderson CAM; Aspry KE; Bolick JP; Kris-Etherton PM; Maki KC
    J Clin Lipidol; 2023; 17(4):428-451. PubMed ID: 37271600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remnant cholesterol, vascular risk, and prevention of atherosclerosis.
    Pintó X; Fanlo M; Esteve V; Millán J;
    Clin Investig Arterioscler; 2023; 35(4):206-217. PubMed ID: 36889989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies.
    Tada H; Nohara A; Kawashiri MA
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertriglyceridemia and atherosclerosis.
    Peng J; Luo F; Ruan G; Peng R; Li X
    Lipids Health Dis; 2017 Dec; 16(1):233. PubMed ID: 29212549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remnant lipoprotein particles and cardiovascular disease risk.
    Krauss RM; King SM
    Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101682. PubMed ID: 35718703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments.
    Reyes-Soffer G
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):85-89. PubMed ID: 33481422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
    Drexel H; Tamargo J; Kaski JC; Lewis BS; Saely CH; Fraunberger P; Dobrev D; Komiyama M; Plattner T; Agewall S; Hasegawa K
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):570-582. PubMed ID: 37328424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triglycerides and risk of atherosclerotic cardiovascular disease: An update.
    Farnier M; Zeller M; Masson D; Cottin Y
    Arch Cardiovasc Dis; 2021 Feb; 114(2):132-139. PubMed ID: 33546998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.
    Borén J; Williams KJ
    Curr Opin Lipidol; 2016 Oct; 27(5):473-83. PubMed ID: 27472409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
    Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV
    J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
    Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
    Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment.
    Varbo A; Benn M; Nordestgaard BG
    Pharmacol Ther; 2014 Mar; 141(3):358-67. PubMed ID: 24287311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
    Iida K; Tani S; Atsumi W; Yagi T; Kawauchi K; Matsumoto N; Hirayama A
    Coron Artery Dis; 2017 Nov; 28(7):577-587. PubMed ID: 28692480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remnant cholesterol and low-grade inflammation jointly in atherosclerotic cardiovascular disease: implications for clinical trials.
    Elías-López D; Doi T; Nordestgaard BG; Kobylecki CJ
    Curr Opin Clin Nutr Metab Care; 2024 Mar; 27(2):125-135. PubMed ID: 38320159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review.
    Sascău R; Clement A; Radu R; Prisacariu C; Stătescu C
    Nutrients; 2021 May; 13(6):. PubMed ID: 34067469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.